scholarly journals AB0732 Efficacy and safety of rituximab in systemic sclerosis: french retrospective study and literature review

2018 ◽  
Author(s):  
M. Thiébaut ◽  
D. Launay ◽  
S. Rivière ◽  
T. Mahévas ◽  
S. Bellakhal ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Systemic Sclerosis ◽  
Literature Review ◽  
Efficacy And Safety

Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review

2018 ◽  
Vol 17 (6) ◽  
pp. 582-587 ◽  
Author(s):  
Mathilde Thiebaut ◽  
David Launay ◽  
Sébastien Rivière ◽  
Thibault Mahévas ◽  
Syrine Bellakhal ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Systemic Sclerosis ◽  
Literature Review ◽  
Efficacy And Safety

Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study

2018 ◽  
Vol 28 (6) ◽  
pp. 1009-1015 ◽  
Author(s):  
Junichi Konma ◽  
Takuya Kotani ◽  
Takeshi Shoda ◽  
Takayasu Suzuka ◽  
Youhei Fujiki ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Systemic Sclerosis ◽  
Combination Therapy ◽  
Interstitial Pneumonia ◽  
Efficacy And Safety

scholarly journals Efficacy of tocilizumab for refractory Takayasu arteritis: a retrospective study and literature review

2021 ◽  
Author(s):  
Haiyan Li ◽  
Zongwen Shuai
Keyword(s):  
Adverse Effect ◽  
Retrospective Study ◽  
Literature Review ◽  
Adverse Events ◽  
Takayasu Arteritis ◽  
Common Adverse Effect ◽  
Efficacy And Safety ◽  
Significant Drop ◽  
Medical University

AbstractTo evaluate the efficacy and safety of tocilizumab (TCZ) in the treatment of refractory Takayasu arteritis (TAK). Eleven refractory TAK patients treated with TCZ at the First Affiliated Hospital of Anhui Medical University between 2017 July and 2020 December were respectively analyzed. We also respectively analyzed the studies on TCZ efficacy in patients with TAK, from PubMed/MEDLINE, Elsevier Science Direct between January 2010 and April 2021. The median age of 11 patients was 34(19–46) years. After 3 months of TCZ, a significant drop was found in median NIH (3[2–5] at baseline vs 1[0–2] after 6 months; p < 0.05), ITAS-2010 score (8.5[6–11] vs 6[1–10]; p < 0.05). One (9%) patient experienced relapse during TCZ treatment. After withdrawal of TCZ, one patient (9%) underwent relapse and nine patients (81%) were spared of GC use. In literature review, a total of 211 patients (mean age 35 years) were analyzed, including 80 (38%) Chinese and 169 females (80%). Among the 211 patients, (154 patients) 73% achieved remission after the last infusion of TCZ; TAK relapsed in 6% of patients during TCZ treatment and 5% of the TCZ patients after the withdrawal of TCZ. A total of 95 types of adverse events were observed in the literature. Infection was the most common adverse effect, occurring in 50% of patients. TCZ could serve as an efficacious and safe agent for refractory TAK.

Efficacy and safety of 308‐nm excimer lamp in the treatment of scalp psoriasis: a retrospective study

2019 ◽  
Vol 35 (3) ◽  
pp. 172-177
Author(s):  
Ploysyne Rattanakaemakorn ◽  
Phanitchanat Phusuphitchayanan ◽  
Kallapan Pakornphadungsit ◽  
Kunlawat Thadanipon ◽  
Poonkiat Suchonwanit
Keyword(s):  
Retrospective Study ◽  
Efficacy And Safety ◽  
Excimer Lamp ◽  
Scalp Psoriasis

scholarly journals The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study

2019 ◽  
Vol Volume 13 ◽  
pp. 3419-3424 ◽  
Author(s):  
Jiangtao Yu ◽  
Ziwen Xu ◽  
Anyang Li ◽  
Jindi Zhang ◽  
Yi Wang ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Retrospective Study ◽  
Efficacy And Safety ◽  
Recurrent Cervical Cancer

scholarly journals Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN)-initiated literature review

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Huai Leng Pisaniello ◽  
Mark C. Fisher ◽  
Hamish Farquhar ◽  
Ana Beatriz Vargas-Santos ◽  
Catherine L. Hill ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Literature Review ◽  
Interleukin 1 ◽  
Treatment Options ◽  
Cochrane Library ◽  
Efficacy And Safety ◽  
Clinical Trial Results ◽  
Gout Flare

AbstractGout flare prophylaxis and therapy use in people with underlying chronic kidney disease (CKD) is challenging, given limited treatment options and risk of worsening renal function with inappropriate treatment dosing. This literature review aimed to describe the current literature on the efficacy and safety of gout flare prophylaxis and therapy use in people with CKD stages 3–5. A literature search via PubMed, the Cochrane Library, and EMBASE was performed from 1 January 1959 to 31 January 2018. Inclusion criteria were studies with people with gout and renal impairment (i.e. estimated glomerular filtration rate (eGFR) or creatinine clearance (CrCl) < 60 ml/min/1.73 m2), and with exposure to colchicine, interleukin-1 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids. All study designs were included. A total of 33 studies with efficacy and/or safety analysis stratified by renal function were reviewed—colchicine (n = 20), anakinra (n = 7), canakinumab (n = 1), NSAIDs (n = 3), and glucocorticoids (n = 2). A total of 58 studies reported these primary outcomes without renal function stratification—colchicine (n = 29), anakinra (n = 10), canakinumab (n = 6), rilonacept (n = 2), NSAIDs (n = 1), and glucocorticoids (n = 10). Most clinical trials excluded study participants with severe CKD (i.e. eGFR or CrCl of < 30 mL/min/1.73 m2). Information on the efficacy and safety outcomes of gout flare prophylaxis and therapy use stratified by renal function is lacking. Clinical trial results cannot be extrapolated for those with advanced CKD. Where possible, current and future gout flare studies should include patients with CKD and with study outcomes reported based on renal function and using standardised gout flare definition.

Sign in / Sign up

Export Citation Format

Share Document